Concepedia

John M. Wallmark

JM

Statistics

Publications

9

Citations

1.1K

H-Index

9

Active since

2000

Affiliations

Princess Margaret Cancer Centre(Current)

The University of Texas MD Anderson Cancer Center

Institut Claudius Regaud

Seoul National University Hospital

Merck & Co., Inc., Rahway, NJ, USA (United States)

John M. Wallmark is an author at Princess Margaret Cancer Centre specializing in medicine, radiation oncology, and cancer therapeutics.

Top concepts

Publications per year

2000–2021

9

Publications

9

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

Aaron R. Hansen, Christophe Massard, Patrick A. Ott et al. · Annals of Oncology · 2018 · 364 citations

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

Bert H. O’Neil, John M. Wallmark, David Lorente et al. · PLoS ONE · 2017 · 299 citations · Full text

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma

Roger B. Cohen, Jean‐Pierre Delord, Toshihiko Doi et al. · American Journal of Clinical Oncology · 2018 · 202 citations · Full text

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

Joyce O’Shaughnessy, Susana Sousa, Josefina Cruz et al. · European Journal of Cancer · 2021 · 67 citations · Full text

Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study

Aaron R. Hansen, Christophe Massard, P.A. Ott et al. · Annals of Oncology · 2016 · 48 citations · Full text

, , +7

Rows per page

1–5 of 9